Key result
ANGPTL3 inhibitor evinacumab safely delivers strong LDL reductions in homozygous familial hypercholesterolemia.
Why the study?
Does evinacumab improve LDL-C levels in patients with homozygous familial hypercholesterolemia?
Does evinacumab improve LDL-C levels in patients with homozygous familial hypercholesterolemia?
Evinacumab provides a promising, LDL receptor-independent therapeutic option with strong LDL-lowering efficacy for patients with homozygous familial hypercholesterolemia.
May expand HoFH options via ANGPTL3 inhibition; leaves open need for outcome trials.
Homozygous familial hypercholesterolemia (HoFH) is a life-threatening disease characterized by extremely elevated LDL cholesterol (LDL-C) levels which result in premature atherosclerotic cardiovascular disease. As conventional lipid-lowering therapies, which mainly depend on LDL receptors for LDL particle clearance, remain insufficient for reaching the recommended LDL-C levels in HoFH, agents acting independently of LDL receptors, such as ANGPTL3 inhibitors, constitute a promising target. Evinacumab, a monoclonal antibody directed against ANGPTL3, was approved in the USA in 2021 for treating patients with HoFH. Evinacumab has shown an adequate safety profile with strong LDL-lowering efficacy. This review highlights the development path of evinacumab and provides insight on the lessons learned from trials as well as the hurdles facing accessibility.
No takes yet. Share an insight, caveat, or question.
Khoury et al. (2022) conducted a review in Homozygous familial hypercholesterolemia (HoFH). Evinacumab was evaluated. Evinacumab, a monoclonal antibody directed against ANGPTL3, has shown an adequate safety profile with strong LDL-lowering efficacy for treating patients with homozygous familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: